S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Precision BioSciences Stock Forecast, Price & News

-0.29 (-2.14 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $13.29
50-Day Range
MA: $9.29
52-Week Range
Now: $13.29
Volume1.79 million shs
Average Volume1.51 million shs
Market Capitalization$697.46 million
P/E RatioN/A
Dividend YieldN/A
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.


Overall MarketRank

1.52 out of 5 stars

Medical Sector

405th out of 1,923 stocks

Biological Products, Except Diagnostic Industry

54th out of 177 stocks

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:DTIL



Sales & Book Value

Annual Sales$22.24 million
Book Value$2.72 per share


Net Income$-92,880,000.00
Net Margins-484.81%


Market Cap$697.46 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
-0.29 (-2.14 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DTIL News and Ratings via Email

Sign-up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Precision BioSciences (NASDAQ:DTIL) Frequently Asked Questions

How has Precision BioSciences' stock been impacted by COVID-19 (Coronavirus)?

Precision BioSciences' stock was trading at $6.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DTIL shares have increased by 104.8% and is now trading at $13.29.
View which stocks have been most impacted by COVID-19

Is Precision BioSciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Precision BioSciences stock.
View analyst ratings for Precision BioSciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Precision BioSciences?

Wall Street analysts have given Precision BioSciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Precision BioSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences CEO Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among Precision BioSciences' employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Precision BioSciences' next earnings date?

Precision BioSciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Precision BioSciences

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) issued its quarterly earnings results on Sunday, November, 15th. The company reported ($0.50) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.66) by $0.16. The company earned $7.36 million during the quarter, compared to the consensus estimate of $4.25 million. Precision BioSciences had a negative net margin of 484.81% and a negative trailing twelve-month return on equity of 105.74%.
View Precision BioSciences' earnings history

What price target have analysts set for DTIL?

6 analysts have issued 12 month price targets for Precision BioSciences' stock. Their forecasts range from $10.00 to $22.00. On average, they expect Precision BioSciences' share price to reach $17.25 in the next year. This suggests a possible upside of 29.8% from the stock's current price.
View analysts' price targets for Precision BioSciences
or view Wall Street analyst' top-rated stocks.

Are investors shorting Precision BioSciences?

Precision BioSciences saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 2,760,000 shares, an increase of 30.8% from the December 15th total of 2,110,000 shares. Based on an average daily trading volume, of 1,000,000 shares, the days-to-cover ratio is currently 2.8 days. Approximately 6.3% of the company's shares are sold short.
View Precision BioSciences' Short Interest

Who are some of Precision BioSciences' key competitors?

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

Who are Precision BioSciences' key executives?

Precision BioSciences' management team includes the following people:
  • Mr. Matthew R. Kane, Co-Founder, CEO, Pres & Director (Age 43, Pay $562.1k)
  • Mr. Dario Scimeca, Gen. Counsel & Sec. (Age 45, Pay $319.96k)
  • Dr. Christopher R. Heery, Chief Medical Officer (Age 40, Pay $444.03k)
  • Dr. Jefferson J. Smith Ph.D., Co-Founder & CTO
  • Mr. Abid Ansari, Chief Financial Officer (Age 42)
  • Dr. David S. Thomson Ph.D., Chief Operating Officer (Age 59)
  • Dr. Derek Jantz Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 44)
  • Mr. John Alexander Kelly, Chief Corp. Affairs Officer & Investor Contact (Age 54)
  • Mr. Bruce Stevens, VP of Quality & Compliance
  • Ms. Heather King, Director of Marketing Communications & PR

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an initial public offering on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.01%). Company insiders that own Precision BioSciences stock include Christopher Heery, Global Strategic Fund Venbio and Tony Dung Ling Yao.
View institutional ownership trends for Precision BioSciences

Which major investors are buying Precision BioSciences stock?

DTIL stock was bought by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Precision BioSciences stock in the last two years include Christopher Heery, Global Strategic Fund Venbio, and Tony Dung Ling Yao.
View insider buying and selling activity for Precision BioSciences
or or view top insider-buying stocks.

How do I buy shares of Precision BioSciences?

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $13.29.

How big of a company is Precision BioSciences?

Precision BioSciences has a market capitalization of $697.46 million and generates $22.24 million in revenue each year. The company earns $-92,880,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Precision BioSciences employs 223 workers across the globe.

What is Precision BioSciences' official website?

The official website for Precision BioSciences is www.precisionbiosciences.com.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at 919-314-5512 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.